<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505921</url>
  </required_header>
  <id_info>
    <org_study_id>ID02-645</org_study_id>
    <nct_id>NCT00505921</nct_id>
  </id_info>
  <brief_title>Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma</brief_title>
  <official_title>Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To evaluate the role of autologous and allogenic stem cell transplantation with
           Campath-1H for patients with peripheral T-cell lymphoma (PTCL).

        2. To examine the impact of in-vivo purging with Campath -1H pre-autologous stem
           transplantation for patients with PTCL.

        3. To evaluate the impact of soluble CD52 upon in-vivo purging with Campath-1H.

        4. To evaluate the role of Campath -1H in the treatment minimal residual disease after
           autologous transplantation for PTCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Campath is a drug that can specifically attack some types of T-cell lymphoma cells.

      Before the study begins, you will have a physical exam, including blood (about 2 tablespoons)
      and urine tests. Women who are able to have children must have a negative blood pregnancy
      test. Bone marrow samples will be taken. To collect a bone marrow sample, an area of the hip
      or chest bone is numbed with anaesthetic and a small amount of bone marrow is withdrawn
      through a large needle. Patients will have a chest x-ray, an EKG (test to measure the
      electrical activity of the heart), and tests of lung function. Patients whose disease affects
      the stomach or intestines may have biopsies of these areas.

      Treatment will be given in the hospital at M. D. Anderson. You will need to stay in the
      hospital for about 3 to 4 weeks.

      A central venous catheter (plastic tube) will be placed into the large chest vein. The
      catheter will be left in place throughout treatment. In order to collect stem cells, G-CSF
      and GM-CSF will be injected under the skin. This will be done twice a day until the
      collection of stem cells is complete. You will receive Campath -1H through the catheter on
      Days 1, 2, 3, and 10 of chemotherapy treatment.

      The stem cells will be collected from you starting about 10 to 14 days after chemotherapy is
      given. The collection process is called apheresis. Blood is removed from the your body and
      the stem cells are frozen for storage. Stem cell collection takes about 3 hours. Between 3
      and 5 sessions may be needed to collect enough stem cells. Sessions will be done once a day.

      After stem cells are collected, you will receive high dose Carmustine over 1 hour on Day 1.
      You will receive cytarabine and etoposide twice a day on Days 2 through 5 and melphalan on
      Day 6.

      One day after finishing the chemotherapy, the stem cells that were collected earlier will be
      infused back into you over about 30 minutes. G-CSF and GM-CSF will be injected until your
      white blood cell counts returns to normal.

      Blood tests (1-2 tablespoons), urine tests, bone marrow sampling, and x-rays will be done as
      needed to track the effects of the transplant. You will have transfusions of blood and
      platelets as needed. Blood tests (1-2 tablespoons) will be done daily while you are in the
      hospital.

      You might have to stay in the Houston area for 2 to 4 weeks after the transplant. After that,
      you will need to return to Houston every 3 months for the first year, then every 6 months for
      5 years. Three months after the transplant, bone marrow exams and other tests will be done.
      If you show evidence of disease, you will receive another cycle of Campath -1H three times a
      week for 4-12 weeks. Patients will be taken off study if the disease gets worse or
      intolerable side effects occur.

      This is an investigational study. The FDA has approved the drugs used in this study. Their
      use together in this study is investigational. About 30 patients will take part in this
      study. All will be enrolled at M. D. Anderson.

      Nonmyeloablative Allogeneic Transplantation with Campath-1H for T-cell Lymphoma:

      Campath is a drug that can specifically attack some types of T-cell lymphoma cells. In
      addition, it weakens the immune system, therefore helping to prevent the rejection of donor
      marrow or stem cells.

      TBI is designed to damage the DNA (the genetic material of cells) of cancer cells, which may
      kill the cancer cells.

      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may
      slow or stop their growth and spread throughout the body. This may cause the cancer cells to
      die.

      Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may
      increase the likelihood of the cells dying.

      Before the study begins, you will have a physical exam, including blood (about 1-2
      tablespoons) and urine tests. Women who are able to have children must have a negative blood
      pregnancy test. Bone marrow samples will be taken. To collect a bone marrow sample, an area
      of the hip or chest bone is numbed with anaesthetic and a small amount of bone marrow is
      withdrawn through a large needle. You will have a chest x-ray, CT scans, an EKG (test to
      measure the electrical activity of the heart), and tests of lung function.

      Blood tests (1-2 tablespoons), urine tests, bone marrow sampling, and x-rays will be done as
      needed to track the effects of the transplant. Patients will have transfusions of blood and
      platelets as needed. Blood tests (1-2 tablespoons) will be done daily while you are in the
      hospital.

      Campath-1 H will be injected into your vein. This will be done 3 days in a row (Days 1 to 3).
      The drugs diphenhydramine (Benadryl), acetaminophen (Tylenol) and hydrocortisone will be
      given in to decrease the risk of or ease side effects.

      You will also receive fludarabine and cyclophosphamide daily for 3 days. They will be given
      starting day of Campath -1H.

      All of the chemotherapy drugs will be given through a catheter (plastic tube) that extends
      into the large chest vein. The catheter will be left in place throughout treatment. After
      completion of chemotherapy, you will receive TBI, and later on the same day, blood stem cells
      from a donor will be given through the catheter. G-CSF and GM-CSF, growth factors that
      promote the production of blood cells, will be injected under the skin once a day until the
      neutrophil counts recover in the blood.

      Tacrolimus will be infused through the vein, starting 2 days before transplant to decrease
      the risk of graft-versus-host disease. It will be changed to pills after you are discharged
      from the hospital. For the same purpose, methotrexate will also be given through the vein on
      Days 1, 3, 6 (and Day 11 if unrelated donor).

      Treatment will be given in the hospital at UTMDACC. You will need to stay in the hospital for
      about 3 to 4 weeks.

      You must stay in the Houston area for about 100 days after the transplant. After that, you
      will need to return to Houston every three months for the first year, then every 6 months for
      5 years for blood tests (1-2 tablespoons), urine tests, and CT scans. Bone marrow aspirations
      and biopsies will also be performed. Patients will be taken off study if the intolerable side
      effects occur.

      This is an investigational study. The FDA has approved the drugs used in this study. Their
      use together in this study is investigational. About 30 patients will take part in this
      study. All will be enrolled at UTMDACC.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual.
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Progression Free Survival at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival defined as the number of participants without evidence of progression or death after 2 years from stem cell transplant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Campath-1H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath-1H</intervention_name>
    <description>3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Alemtuzumab</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Granulocyte colony-stimulating factor</other_name>
    <other_name>GCSF</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Granulocyte-Macrophage Colony Stimulating Factor</other_name>
    <other_name>Sargramostim</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>300 mg/m2 IV over 1 hour on day -6</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Carmustine</other_name>
    <other_name>BiCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>SCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preparative Regimen for Allogenic Stem Cell Transplantation</intervention_name>
    <description>Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.</description>
    <arm_group_label>Campath-1H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>ARA</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>200 mg/m2 IV twice on day -5 to -2 (total 8 doses)</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Etoposide phosphate</other_name>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m2 IV on day -1.</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Alemtuzumab</other_name>
    <other_name>Campath-1H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 IV/day (days -6 to -4)</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Fludarabine monophosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low dose total body irradiation</intervention_name>
    <description>Low dose total body irradiation of 2 Gy day 0.</description>
    <arm_group_label>Campath-1H</arm_group_label>
    <other_name>LD-TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be less then 70 years old.

          -  Patients must have chemosensitive disease, having undergone at least partial remission
             with less then 10% marrow involvement by gross pathologic examination if autologous
             transplantation is considered.

          -  Newly diagnosed patients are eligible for autologous transplant. Patients in relapse
             would receive a non-myeloablative transplant if a sibling donor is available.
             Otherwise, patients would undergo autologous transplant if International Prognostic
             Index (IPI) is 0-1, or unrelated transplant if IPI is &gt; 1.

        Exclusion Criteria:

          -  Criteria for exclusion are Human immunodeficiency virus (HIV) or Human T-lymphotropic
             virus (HTLV) seropositivity, pregnancy, cardiac ejection fraction by echo-cardiogram
             less than 40%, active central nervous system involvement, serum creatinine greater
             than 1.6 mg/dl or serum bilirubin greater than 1.5 mg/dl unless due to tumor, Absolute
             neutrophil count (ANC) less than 1,000/mm3 and platelets less than 100,000/mm3 unless
             due to tumor, performance status (ECOG scale) greater than 2, pulmonary function test-
             diffusing capacity of the Lung for Carbon Monoxide (DLCO) less than 40% of predicted,
             and severe concomitant medical or psychiatric illnesses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>September 30, 2011</results_first_submitted>
  <results_first_submitted_qc>September 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2011</results_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-Cell Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Campath-1H</keyword>
  <keyword>Allogenic Transplantation</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Alemtuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 3/11/2003 to 10/27/2009. All participants were registered at UT MD Anderson Cancer Center</recruitment_details>
      <pre_assignment_details>Eight patients of those twenty-seven registered failed to mobilize an adequate number of stem cells for an autologous transplant and were taken off the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Campath-1H</title>
          <description>3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to Mobilize</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Campath-1H</title>
          <description>3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="0" lower_limit="22" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Progression Free Survival at 2 Years</title>
        <description>Progression-free survival defined as the number of participants without evidence of progression or death after 2 years from stem cell transplant.</description>
        <time_frame>2 years</time_frame>
        <population>Analysis was per protocol. Nine participants were not eligible for treatment therefore were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Campath-1H</title>
            <description>3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Progression Free Survival at 2 Years</title>
          <description>Progression-free survival defined as the number of participants without evidence of progression or death after 2 years from stem cell transplant.</description>
          <population>Analysis was per protocol. Nine participants were not eligible for treatment therefore were excluded from analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years and 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Campath-1H</title>
          <description>3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>low blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Alkaine Phos</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>ALT- Transaminase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>AST-Tranaminase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>increased bilirubin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>fevers</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>neutropenia infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>involuntary movement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>neurological other complaints</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>pulmonary other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to slow accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Issa F. Khouri, MD / Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-8848</phone>
      <email>pmcadams@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

